Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Feb;117(3):516–520. doi: 10.1111/j.1476-5381.1996.tb15220.x

Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.

M A Vieira-Coelho 1, P Soares-da-Silva 1
PMCID: PMC1909301  PMID: 8821542

Abstract

1. The present work describes the catechol-O-methyltransferase (COMT) activities in the liver and kidney of developing and adult rats (aged 3, 6, 9, 18, 30 and 60 days; n = 5 per group) and evaluates the enzyme sensitivity to inhibition by tolcapone, a reversible COMT inhibitor. 2. COMT activity, evaluated by the ability to methylate adrenaline to metanephrine, was determined in liver and kidney homogenates prepared in 0.5 mM phosphate buffer (pH = 7.8) containing pargyline (0.1 mM), MgCl2 (0.1 mM), EGTA (1 mM) and S-adenosyl-L-methionine (0.1 mM). Vmax (in nmol mg-1 protein h-1) of liver COMT was found to decrease gradually with age, from 5.3 +/- 0.5 at the age of 3 days up to 2.9 +/- 0.2 at the age of 60 days; for the same age range, Km values (in microM; geometric means with 95% confidence limits) increased from 3.3 (1.0, 7.5) up to 13.1 (2.1, 24.1). At the age of 3 days, Vmax values for kidney COMT (2.6 +/- 0.1) were lower than those for the liver COMT. However, Vmax values for kidney COMT were found to increase up to 6.2 +/- 0.6 at the age of 18 days and then declined by 44% at the age of 30 and 60 days. In kidney, aging was also accompanied by an increase in Km values for COMT (from 2.7 [1.1, 4.3] up to 24.0 [11.7, 36.3]). 3. The sensitivity of liver and renal COMT activity to tolcapone was markedly dependent on the age, 3-days old rats being more sensitive to tolcapone than older animals. The IC50 values (in nM) for inhibition of liver COMT by tolcapone increased gradually with age, from 41 (26, 65) at the age of 3 days up to 720 (640, 800) at the age of 60 days. As was found in the liver, IC50 values (in nM) for inhibition of kidney COMT by tolcapone also increased with age, from 8 (6, 10) at the age of 3 days up to 177 (131, 240) at the age of 60 days. In all experimental groups, the IC50 values for inhibition of liver COMT by tolcapone was higher than those for kidney COMT. 4. In conclusion, these results suggest that aging is accompanied by a decrease in liver and kidney COMT affinity for the substrate (evidenced by the increase in Km values) and a decrease in sensitivity towards inhibition by tolcapone (evidenced by the increase in IC50 values). Furthermore, kidney COMT is shown to be more sensitive to inhibition by tolcapone than liver COMT, irrespective of the age of the animal.

Full text

PDF
516

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AXELROD J., TOMCHICK R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958 Sep;233(3):702–705. [PubMed] [Google Scholar]
  2. Aprille J. R., Malamud D. F. Catechol-O-methyl transferase in mouse liver plasma membranes. Biochem Biophys Res Commun. 1975 Jun 16;64(4):1293–1302. doi: 10.1016/0006-291x(75)90833-5. [DOI] [PubMed] [Google Scholar]
  3. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev. 1966 Mar;18(1):95–113. [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  5. Guldberg H. C., Marsden C. A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975 Jun;27(2):135–206. [PubMed] [Google Scholar]
  6. Kopin I. J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev. 1985 Dec;37(4):333–364. [PubMed] [Google Scholar]
  7. Lee M. R. Dopamine and the kidney: ten years on. Clin Sci (Lond) 1993 Apr;84(4):357–375. doi: 10.1042/cs0840357. [DOI] [PubMed] [Google Scholar]
  8. Meister B., Bean A. J., Aperia A. Catechol-O-methyltransferase mRNA in the kidney and its appearance during ontogeny. Kidney Int. 1993 Oct;44(4):726–733. doi: 10.1038/ki.1993.306. [DOI] [PubMed] [Google Scholar]
  9. Männistö P. T., Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci. 1989 Feb;10(2):54–56. doi: 10.1016/0165-6147(89)90075-8. [DOI] [PubMed] [Google Scholar]
  10. Roth J. A. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol. 1992;120:1–29. doi: 10.1007/BFb0036121. [DOI] [PubMed] [Google Scholar]
  11. Soares-da-Silva P., Fernandes M. H., Pinto-do-O P. C. Cell inward transport of L-DOPA and 3-O-methyl-L-DOPA in rat renal tubules. Br J Pharmacol. 1994 Jun;112(2):611–615. doi: 10.1111/j.1476-5381.1994.tb13118.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tong J. H., D'Iorio A. Solubilization and partial purification of particulate catechol-O-methyltransferase from rat liver. Can J Biochem. 1977 Oct;55(10):1108–1113. doi: 10.1139/o77-164. [DOI] [PubMed] [Google Scholar]
  13. Vidgren J., Svensson L. A., Liljas A. Crystal structure of catechol O-methyltransferase. Nature. 1994 Mar 24;368(6469):354–358. doi: 10.1038/368354a0. [DOI] [PubMed] [Google Scholar]
  14. Vieira-Coelho M. A., Fernandes M. H., Soares-da-Silva P. In vivo effects of the monoamine oxidase inhibitors Ro 41-1049 and Ro 19-6327 on the production and fate of renal dopamine. J Neural Transm Suppl. 1994;41:365–370. doi: 10.1007/978-3-7091-9324-2_48. [DOI] [PubMed] [Google Scholar]
  15. Zürcher G., Colzi A., Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl. 1990;32:375–380. doi: 10.1007/978-3-7091-9113-2_51. [DOI] [PubMed] [Google Scholar]
  16. Zürcher G., Keller H. H., Kettler R., Borgulya J., Bonetti E. P., Eigenmann R., Da Prada M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol. 1990;53:497–503. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES